Co-Diagnostics, Inc. (CODX) stock
Close on Nov 13, 2026Market cap $1.62MP/E –Yield –
Co-Diagnostics, Inc. grew revenue 69.1% to $858.89K over the twelve months to Sep 30, 2026. Free cash flow was -$27.19M. At the latest close the market valued the company at $1.62M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $1.62M
- P/E ratio
- –
- Price to sales
- 1.88
- Price to book
- 0.17
- Dividend yield
- –
- Free cash flow yield
- -1681.66%
Fundamentals
- Revenue
- $858.89K
- Net income
- -$47.48M
- EPS, diluted
- -$20.20
- Free cash flow
- -$27.19M
- Book value per share
- $1.50
- Diluted shares
- 6M
Trading
- Next earnings
- Mar 30, 2027 (estimated, after the close)
- Previous close
- $0.27
- Open
- $0.27
- Day's range
- $0.24 – $0.27
- Volume
- 591,938
- Average volume (20 days)
- 5,619,706
- Beta (5 years)
- 1.74
- 52-week range
- $0.24 – $13.54
- RSI (14 days)
- 23.2
- Volatility (1 year)
- 220.9%
- Relative volume
- 0.39×
- WACC
- 13.8%
Market cap history
Month-end market cap since 2017, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 13, 2026. The S&P 500 is measured by the SPY fund.
| Period | CODX | S&P 500 | Difference | CODX per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -75.7% | -3.0% | −72.7 pts | ||
| 3 months | -82.6% | -2.8% | −79.9 pts | ||
| Year to date | -94.9% | +11.5% | −106.4 pts | ||
| 1 year | -97.7% | +13.5% | −111.1 pts | ||
| 3 years | -99.3% | +77.7% | −176.9 pts | -80.4% | +21.1% |
| 5 years | -99.9% | +72.6% | −172.5 pts | -75.3% | +11.5% |
Eleven years at a glance
Fiscal years 2015 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Co-Diagnostics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Update
- News
- Results
- News
- Results
About Co-Diagnostics
Surgical & Medical Instruments & Apparatus
Co-Diagnostics, Inc. develops, manufactures, and sells molecular diagnostics reagents and testing systems that detect and analyze nucleic acid molecules. The company utilizes its proprietary Co-Primers polymerase chain reaction technology to produce diagnostic tests for infectious diseases, including COVID-19, influenza, tuberculosis, hepatitis, human papillomavirus, malaria, dengue, and Zika. In addition to human medical tests, it provides solutions for identifying genetic traits in plant and animal genomes as well as mosquito surveillance tests. It also develops the portable Co-Dx PCR platform comprising testing instruments, test cups, and mobile software. Its offerings serve clinical laboratories, research partners, and municipal organizations.
Company profile, executives and historyCo-Diagnostics stock: common questions
What is Co-Diagnostics's stock price?
CODX closed at $0.26 on Nov 13, 2026, down 4.12% on the day. Over the past 52 weeks it traded between $0.24 and $13.54.
What is Co-Diagnostics's market cap?
Co-Diagnostics was worth $1.62M at the close on Nov 13, 2026: the share price times the diluted shares outstanding.
What is CODX's P/E ratio?
Co-Diagnostics lost money over the twelve months to Sep 30, 2026 (diluted EPS -$20.20), so it has no meaningful P/E ratio.
How much revenue does Co-Diagnostics make?
Co-Diagnostics reported revenue of $858.89K for the twelve months to Sep 30, 2026, up 69.1% from a year earlier.
Does Co-Diagnostics pay a dividend?
No. Co-Diagnostics has not paid a cash dividend over the last twelve months.
When does Co-Diagnostics report earnings next?
Co-Diagnostics is expected to report Q4 FY2026 results on Mar 30, 2027, after the close. The date is estimated from its past reporting pattern until the company confirms it.
How has CODX stock performed over the past year?
Including dividends, CODX returned -97.7% over the past year, against +13.5% for the S&P 500.
How many CODX shares are sold short?
1M shares were sold short at the latest FINRA report, 18.40% of the float, or 2.2 days of average trading volume.
Who are Co-Diagnostics's competitors?
Companies most similar to Co-Diagnostics by business, industry and size include SINT, INBS, PETV, FEMY, HRGN.
See a number that looks wrong?